{"entity":{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","aka":[],"tldr":"Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy.","summary":"Ferdinandos Skoulidis was lead author of the phase 2 CodeBreaK 100 report that won sotorasib accelerated approval for KRAS G12C-mutant NSCLC, closing forty years of KRAS being undruggable. His earlier work showed that STK11 and KEAP1 co-mutations define an immunotherapy-resistant subgroup of KRAS-mutant lung cancer. He continues to lead KRAS combination trials at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS"}],"tags":["lung","kras","targeted-therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":["sotorasib","adagrasib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["codebreak-200"],"people":[],"bottlenecks":[],"keyPapers":["paper-codebreak-200-lancet-2023","paper-ostrem-kras-g12c-nature-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["KRAS-mutant lung cancer","Co-mutations and immunotherapy resistance","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS"}],"papers":[{"title":"Sotorasib for lung cancers with KRAS p.G12C mutation (CodeBreaK 100)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103695"},{"title":"STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","journal":"Cancer Discovery","year":2018,"doi":"10.1158/2159-8290.CD-18-0099"},{"title":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CodeBreaK+200+sotorasib+docetaxel+de+Langen+Lancet"},{"title":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","journal":"Nature","year":2013,"url":"https://doi.org/10.1038/nature12796","doi":"10.1038/nature12796"}]},"route":"/people/ferdinandos-skoulidis/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/"}],"paper":[{"id":"paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","kind":"paper","name":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","route":"/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/"},{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/"},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/"}]}}